Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?

Extracorporeal membrane oxygenation (ECMO) is a supportive therapy and definitive management often relies on adequate drug therapy aimed at reversing the underlying cause of cardiac and/or respiratory failure. Despite this, a paucity of data exists describing the impact of ECMO on pharmacokinetics (PK) and antibiotic dosing requirements. By default, clinicians prescribe standard doses to these complicated patients, thereby risking therapeutic failure or toxicity. We report two patients to highlight our concerns with regard to antibiotic therapy in the presence of ECMO. Ethics approval was granted by the local Human Research Ethics Committee (HREC/11/QPCH/121).

[1]  J. Fraser,et al.  Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. , 2012, Journal of critical care.

[2]  Kiran Shekar,et al.  Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation , 2012, Critical Care.

[3]  J. Fraser,et al.  Increased Sedation Requirements in Patients Receiving Extracorporeal Membrane Oxygenation for Respiratory and Cardiorespiratory Failure , 2012, Anaesthesia and intensive care.

[4]  David Stewart,et al.  Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. , 2012, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[5]  D. Paterson,et al.  Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. , 2010, International journal of antimicrobial agents.

[6]  D. Tibboel,et al.  Determinants of drug absorption in different ECMO circuits , 2010, Intensive Care Medicine.

[7]  J. Roberts,et al.  Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration , 2010, Antimicrobial Agents and Chemotherapy.

[8]  M. Roberts,et al.  Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. , 2009, The Journal of antimicrobial chemotherapy.

[9]  Jane Alcorn,et al.  Pharmacokinetics in the newborn. , 2003, Advanced drug delivery reviews.

[10]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.